CHAPTER 92
Substitute for House Bill No. 2250
An Act concerning health and healthcare; relating to certain medications; relating to treatment of sexually transmitted infection treatment; permitting the use of expedited partner therapy for the treatment thereof; authorizing a licensed private psychiatric hospital to maintain a stock supply of emergency medication kits for pharmaceutical emergencies; allowing for the use of expired emergency opioid antagonists to treat an opioid overdose; permitting first responders to distribute and administer expired emergency opioid antagonists; permitting a pharmacist to distribute epinephrine delivery systems to a school for emergency medication kits; amending definitions related to medication in schools to allow for use of epinephrine delivery systems; amending K.S.A. 72-6282 and K.S.A. 2025 Supp. 22-2312, 65-1680, 65-16,127 and 72-6283 and repealing the existing sections.
Be it enacted by the Legislature of the State of Kansas:
New Section 1. (a) As used in this section:
(1) “Department” means the department of health and environment.
(2) “Expedited partner therapy” means to prescribe, administer, dispense or otherwise provide antimicrobial drugs to a sexual partner of a patient clinically diagnosed by a healthcare provider as infected with a sexually transmitted disease without a physical examination of such sexual partner.
(3) “Healthcare provider” means a practitioner or mid-level practitioner as those terms are defined in K.S.A. 65-1626, and amendments thereto.
(4) “Pharmacist” means a person licensed by the state board of pharmacy to practice pharmacy.
(5) “Secretary” means the secretary of health and environment or the secretary’s designee.
(6) “Sexually transmitted disease” means any disease transmitted through sexual contact, defined by rules and regulations adopted by the secretary as a reportable infectious disease under K.S.A. 65-118, and amendments thereto, and designated as appropriate for expedited partner therapy by rules and regulations adopted by the secretary.
(b) (1) A healthcare provider who clinically diagnoses a patient with a sexually transmitted disease may provide expedited partner therapy if, in the professional judgment of the healthcare provider, the patient’s sexual partner is unlikely or unable to present for examination, testing and treatment.
(2) A healthcare provider who provides expedited partner therapy shall provide counseling to the patient, including distributing written materials developed and provided by the department to be given by the patient to the patient’s sexual partner.
(3) A healthcare provider shall use expedited partner therapy only for a patient’s sexual partner who may have been exposed to a sexually transmitted disease within 60 days immediately prior to the patient’s clinical diagnosis and who is able to be contacted and identified by the patient.
(4) A child who is 16 years of age or older may consent to receive expedited partner therapy when no parent or guardian is immediately available.
(c) (1) No healthcare provider or pharmacist shall be liable for civil damages resulting from any act or omission in good faith compliance with the provisions of this section, including civil damages for refusing to provide expedited partner therapy, other than an act or omission constituting gross negligence or intentional or reckless misconduct.
(2) No healthcare provider or pharmacist shall be subject to disciplinary action by the state board of healing arts, the board of nursing or the state board of pharmacy, as applicable, on the basis of an act or omission in good faith compliance with the provisions of this section, other than an act or omission constituting gross negligence or intentional or reckless misconduct.
(d) The department shall include the following information in written materials developed and provided for distribution as required by subsection (b)(2):
(1) A warning that a woman who is pregnant or might be pregnant should not take certain antibiotics and should immediately contact a healthcare provider for an examination;
(2) information about the antimicrobial drug and dosage provided or prescribed, including a warning that a sexual partner who has a history of allergy to the drug or the pharmaceutical class of drug should not take the drug and should immediately contact a healthcare provider for examination;
(3) information about the treatment and prevention of sexually transmitted diseases;
(4) the requirement of sexual abstinence until a period of time after treatment to prevent infecting other sexual partners;
(5) notification of the importance of the sexual partners receiving examination and testing for human immunodeficiency virus and other sexually transmitted diseases and information about available resources;
(6) notification of the risk to the patient, the patient’s sexual partner and the general public if the sexually transmitted disease is not completely and successfully treated;
(7) the responsibility of the sexual partner to inform the sexual partner’s own sexual partners of the risk of sexually transmitted disease and the importance of prompt examination and treatment by a healthcare provider; and
(8) such other information deemed necessary by the secretary.
(e) The secretary shall adopt rules and regulations as necessary to implement and administer this section.
New Sec. 2. (a) A licensed private psychiatric hospital that utilizes the services of a pharmacist may stock and maintain an emergency medication kit approved by such hospital’s medical staff and pharmacist.
(b) The emergency medication kit shall be used only in emergency cases under the supervision and direction of a prescriber and a pharmacist who shall have supervisory responsibility of maintaining such kit.
(c) Drugs in an emergency medication kit shall be maintained under the control of the pharmacist-in-charge of the pharmacy from which the kit came until administered to the patient upon the proper order of a practitioner.
(d) Drugs contained within the emergency medication kit may include controlled substances, but in such a case, a pharmaceutical services committee shall be responsible for specifically limiting the type and quantity of controlled substance to be placed in each emergency kit.
(e) Administration of controlled substances contained within the emergency medication kit shall be in compliance with the provisions of the uniform controlled substances act.
(f) The pharmacist-in-charge of the licensed private psychiatric hospital shall be responsible for developing procedures, proper control and accountability for the emergency kit and maintain complete and accurate records.
(g) The secretary and the state board of pharmacy shall jointly adopt such rules and regulations that are necessary to effectuate the provisions of this act. Such rules and regulations shall include, but not be limited to, the contents of the emergency medication kit, procedures for the control and accountability of the emergency medication kit, recordkeeping and storage of the emergency medication kit.
(h) As used in this section:
(1) “Emergency medication kit” means a stock supply of such drugs as are required to meet the immediate therapeutic needs of patients when the drug is not available from another source in sufficient time to prevent harm;
(2) “licensed private psychiatric hospital” means an institution, excluding state institutions as defined in K.S.A. 76-12a01, and amendments thereto, that is primarily engaged in providing services, by and under the supervision of qualified professionals, for the diagnosis and treatment of mentally ill individuals that is licensed pursuant to K.S.A. 39-2008, and amendments thereto;
(3) “pharmacist” means the same as defined in K.S.A. 65-1626, and amendments thereto;
(4) “pharmacist-in-charge” means the same as defined in K.S.A. 65-1626, and amendments thereto;
(5) “practitioner” means the same as defined in K.S.A. 65-1626, and amendments thereto;
(6) “prescriber” means the same as defined in K.S.A. 65-1626, and amendments thereto; and
(7) “secretary” means the secretary of health and environment.
Sec. 3 K.S.A. 2025 Supp. 22-2312 is hereby amended to read as follows: 22-2312. (a) A law enforcement officer shall not take a person into custody based solely on the commission of an offense described in subsection (b) if the law enforcement officer, after making a reasonable determination and considering the facts and surrounding circumstances, reasonably believes that the person:
(1) (A) Initiated contact with a law enforcement officer, law enforcement agency or emergency medical services and requested medical assistance on the person’s own behalf because the person reasonably believed they needed medical assistance as a result of the use of a controlled substance; and
(B) cooperated with law enforcement officers and emergency medical services personnel in providing such medical assistance;
(2) (A) was a person who rendered aid, including administering an emergency opioid antagonist, to another person who reasonably appeared to need medical assistance as a result of the use of a controlled substance or initiated contact with a law enforcement officer, law enforcement agency or emergency medical services and requested medical assistance for another person who reasonably appeared to need medical assistance as a result of the use of a controlled substance;
(B) provided such person’s full name and any other relevant information that is necessary to provide the medical assistance described in paragraph (2)(A) as requested by law enforcement or emergency medical services;
(C) remained at the scene with the person who reasonably appeared to need medical assistance until emergency medical services personnel and law enforcement officers arrived; and
(D) cooperated with emergency medical services personnel and law enforcement officers in providing such medical assistance; or
(3) (A) was the person who reasonably appeared to need medical assistance as a result of the use of a controlled substance as described in subsection (a)(2)(A); and
(B) cooperated with emergency medical services personnel and law enforcement officers in providing such medical assistance.
(b) (1) Except as provided in paragraph (2), each person who meets the criteria in subsection (a) is immune from criminal prosecution for a violation of K.S.A. 21-5706 or 21-5709(b)(2), and amendments thereto, and any city ordinance or county resolution prohibiting the acts prohibited by K.S.A. 21-5706 or 21-5709(b)(2), and amendments thereto.
(2) No person is immune from criminal prosecution as provided in paragraph (1) if the quantity of controlled substances found at the scene of the encounter with law enforcement would be sufficient to create a rebuttable presumption of an intent to distribute as described in K.S.A. 21-5705(e), and amendments thereto.
(c) The provisions of this section shall not apply to a person seeking medical assistance during the course of the execution of an arrest warrant or search warrant or a lawful search.
(d) Nothing in this section shall be construed to preclude a person who is immune from criminal prosecution pursuant to this section from being prosecuted based on evidence obtained from an independent source.
(e) A person shall not be allowed to initiate or maintain an action against a law enforcement officer, or the officer’s employer, based on the officer’s compliance or failure to comply with this section. Except in cases of reckless or intentional misconduct, a law enforcement officer shall be immune from liability for arresting a person who is later determined to be immune from prosecution pursuant to this section.
(f) As used in this section:
(1) “Controlled substance” means the same as defined in K.S.A. 21-5701, and amendments thereto; and.
(2) “Emergency opioid antagonist” means an intranasal form of a drug that inhibits the effects of opioids and that is approved by the federal food and drug administration for the treatment of an opioid overdose. “Emergency opioid antagonist” includes an expired emergency opioid antagonist up to 10 years past such emergency opioid antagonist’s expiration date.
(2)(3) “Law enforcement officer” means the same as defined in K.S.A. 21-5111, and amendments thereto.
Sec. 4. K.S.A. 2025 Supp. 65-16,127 is hereby amended to read as follows: 65-16,127. (a) As used in this section:
(1) “Bystander” means a family member, friend, caregiver or other person in a position to assist a person who the family member, friend, caregiver or other person believes, in good faith, to be experiencing an opioid overdose.
(2) “Emergency opioid antagonist” means any drug that inhibits the effects of opioids and that is approved by the United States food and drug administration for the treatment of an opioid overdose. Except as provided in subsection (h), “emergency opioid antagonist” includes an expired emergency opioid antagonist up to 10 years past such emergency opioid antagonist’s expiration date.
(3) “First responder” includes any emergency medical service provider, as defined by K.S.A. 65-6112, and amendments thereto, any law enforcement officer, as defined by K.S.A. 22-2202, and amendments thereto, and any actual member of any organized fire department, whether regular or volunteer.
(4) “First responder agency” includes, but is not limited to, any law enforcement agency, fire department or criminal forensic laboratory of any city, county or the state of Kansas.
(5) “Opioid antagonist protocol” means the protocol established by the state board of pharmacy pursuant to subsection (b).
(6) “Opioid overdose” means an acute condition including, but not limited to, extreme physical illness, decreased level of consciousness, respiratory depression, coma, mania or death, resulting from the consumption or use of an opioid or another substance with which an opioid was combined, or that a layperson would reasonably believe to be resulting from the consumption or use of an opioid or another substance with which an opioid was combined, and for which medical assistance is required.
(7) “Patient” means a person believed to be at risk of experiencing an opioid overdose.
(8) “School nurse” means a professional nurse licensed by the board of nursing and employed by a school district to perform nursing procedures in a school setting.
(9) “Healthcare provider” means a physician licensed to practice medicine and surgery by the state board of healing arts, a licensed dentist, a mid-level practitioner as defined by K.S.A. 65-1626, and amendments thereto, or any person authorized by law to prescribe medication.
(b) The state board of pharmacy shall issue a statewide opioid antagonist protocol that establishes requirements for a licensed pharmacist to dispense emergency opioid antagonists to a person pursuant to this section. The opioid antagonist protocol shall include procedures to ensure accurate recordkeeping and education of the person to whom the emergency opioid antagonist is furnished, including, but not limited to: Opioid overdose prevention, recognition and response; safe administration of an emergency opioid antagonist; potential side effects or adverse events that may occur as a result of administering an emergency opioid antagonist; a requirement that the administering person immediately contact emergency medical services for a patient; and the availability of drug treatment programs.
(c) A pharmacist may furnish an emergency opioid antagonist to a patient or bystander subject to the requirements of this section, the pharmacy act of the state of Kansas and any rules and regulations adopted by the state board of pharmacy thereunder.
(d) A pharmacist furnishing an emergency opioid antagonist pursuant to this section may not permit the person to whom the emergency opioid antagonist is furnished to waive any consultation required by this section or any rules and regulations adopted thereunder.
(e) Any first responder, scientist or technician operating under a first responder agency or school nurse is authorized to possess, store, distribute and administer emergency opioid antagonists as clinically indicated, provided that all personnel with access to emergency opioid antagonists are trained, at a minimum, on the following:
(1) Techniques to recognize signs of an opioid overdose;
(2) standards and procedures to store, distribute and administer an emergency opioid antagonist;
(3) emergency follow-up procedures, including the requirement to summon emergency ambulance services either immediately before or immediately after administering an emergency opioid antagonist to a patient; and
(4) inventory requirements and reporting any administration of an emergency opioid antagonist to a healthcare provider.
(f) (1) Any first responder agency electing to provide an emergency opioid antagonist to its employees or volunteers for the purpose of administering the emergency opioid antagonist shall procure the services of a physician to serve as physician medical director for the first responder agency’s emergency opioid antagonist program.
(2) The first responder agency shall utilize the physician medical director or a licensed pharmacist for the purposes of:
(A) Obtaining a supply of emergency opioid antagonists;
(B) receiving assistance developing necessary policies and procedures that comply with this section and any rules and regulations adopted thereunder;
(C) training personnel; and
(D) coordinating agency activities with local emergency ambulance services and medical directors to provide quality assurance activities.
(3) A law enforcement agency shall be exempt from this subsection unless electing to provide an emergency opioid antagonist dispensed or furnished pursuant to the opioid antagonist protocol in subsection (b).
(g) (1) Any healthcare provider or pharmacist who, in good faith and with reasonable care, prescribes or dispenses an emergency opioid antagonist pursuant to this section shall not, by an act or omission, be subject to civil liability, criminal prosecution or any disciplinary or other adverse action by a professional licensure entity arising from the healthcare provider or pharmacist prescribing or dispensing the emergency opioid antagonist.
(2) Any patient, bystander, school nurse, or a first responder, scientist or technician operating under a first responder agency, who, in good faith and with reasonable care, receives and administers an emergency opioid antagonist pursuant to this section to a person experiencing a suspected opioid overdose shall not, by an act or omission, be subject to civil liability or criminal prosecution, unless personal injury results from the gross negligence or willful or wanton misconduct in the administration of the emergency opioid antagonist.
(3) Any first responder agency employing or contracting any person that, in good faith and with reasonable care, administers an emergency opioid antagonist pursuant to this section to a person experiencing a suspected opioid overdose shall not, by an act or omission, be subject to civil liability, criminal prosecution, any disciplinary or other adverse action by a professional licensure entity or any professional review.
(h) Pharmacists, healthcare providers and school nurses shall not prescribe, dispense, distribute or furnish an expired emergency opioid antagonist.
(i) The state board of pharmacy shall adopt rules and regulations as may be necessary to implement the provisions of this section prior to January 1, 2018.
(i)(j) This section shall be a part of and supplemental to the pharmacy act of the state of Kansas.
Sec. 5. K.S.A. 2025 Supp. 65-1680 is hereby amended to read as follows: 65-1680. (a) A pharmacist may distribute a stock supply of standard-dose and pediatric-dose epinephrine auto-injectors delivery systems to a school pursuant to a prescription made pursuant to K.S.A. 72-6283, and amendments thereto, from a physician or mid-level practitioner in the name of the school. A pharmacist who distributes a stock supply of standard-dose or pediatric-dose epinephrine auto-injectors delivery systems to a school shall not be liable for civil damages resulting from the administration of such medication pursuant to this section, K.S.A. 65-2872b or 72-6283, and amendments thereto.
(b) A pharmacist may distribute a stock supply of albuterol metered-dose inhalers, albuterol solution and spacers to a school pursuant to a prescription made pursuant to K.S.A. 72-6283, and amendments thereto, from a physician or mid-level practitioner in the name of the school. A pharmacist who distributes a stock supply of albuterol metered-dose inhalers, albuterol solution or spacers to a school shall not be liable for civil damages resulting from the administration of such medication pursuant to this section, K.S.A. 65-2872b or 72-6283, and amendments thereto.
(c) The terms used in this section mean the same as defined in K.S.A. 72-6283, and amendments thereto.
Sec. 6. K.S.A. 72-6282 is hereby amended to read as follows: 72-6282. (a) As used in this section:
(1) “Medication” means a medicine prescribed by a health care healthcare provider for the treatment of anaphylaxis or asthma, including, but not limited to, any medicine defined in section 201 of the federal food, drug and cosmetic act, inhaled bronchodilators and auto-injectible epinephrine delivery systems.
(2) “Health careHealthcare provider” means:
(A) A physician licensed by the state board of healing arts to practice medicine and surgery; or
(B) an advanced practice registered nurse issued a license pursuant to K.S.A. 65-1131, and amendments thereto, who has authority to prescribe drugs as provided by K.S.A. 65-1130, and amendments thereto; or (C) a physician assistant licensed pursuant to the physician assistant licensure act who has authority to prescribe drugs prior to January 11, 2016, pursuant to a written protocol with a responsible physician under K.S.A. 65-28a08, and amendments thereto, and on and after January 11, 2016, pursuant to a written agreement with a supervising physician under K.S.A. 65-28a08, and amendments thereto a mid-level practitioner as such term is defined in K.S.A. 65-1626, and amendments thereto.
(3) “School” means any public or accredited nonpublic school.
(4) “Self-administration” means a student’s discretionary use of such student’s medication pursuant to a prescription or written direction from a health care healthcare provider.
(b) Each school district shall adopt a policy authorizing the self-administration of medication by students enrolled in kindergarten or any of the grades one through 12. A student shall meet all requirements of a policy adopted pursuant to this subsection. Such policy shall include:
(1) A requirement of a written statement from the student’s health care healthcare provider stating the name and purpose of the medication;, the prescribed dosage;, the time the medication is to be regularly administered, and any additional special circumstances under which the medication is to be administered;, and the length of time for which the medication is prescribed;
(2) a requirement that the student has demonstrated to the health care healthcare provider or such provider’s designee and the school nurse or such nurse’s designee the skill level necessary to use the medication and any device that is necessary to administer such medication as prescribed. If there is no school nurse, the school shall designate a person for the purposes of this subsection;
(3) a requirement that the health care healthcare provider has prepared a written treatment plan for managing asthma or anaphylaxis episodes of the student and for medication use by the student during school hours;
(4) a requirement that the student’s parent or guardian has completed and submitted to the school any written documentation required by the school, including the treatment plan prepared as required by paragraph (3) and documents related to liability;
(5) a requirement that all teachers responsible for the student’s supervision shall be notified that permission to carry medications and self-medicate has been granted; and
(6) any other requirement imposed by the school district pursuant to this section and K.S.A. 72-1138(e), and amendments thereto.
(c) A school district shall require annual renewal of parental authorization for the self-administration of medication.
(d) A school district, and its officers, employees and agents, which that authorizes the self-administration of medication in compliance with the provisions of this section shall not be held liable in any action for damage, injury or death resulting directly or indirectly from the self-administration of medication.
(e) A school district shall provide written notification to the parent or guardian of a student that the school district and its officers, employees and agents are not liable for damage, injury or death resulting directly or indirectly from the self-administration of medication. The parent or guardian of the student shall sign a statement acknowledging that the school district and its officers, employees or agents incur no liability for damage, injury or death resulting directly or indirectly from the self-administration of medication and agreeing to release, indemnify and hold the school and its officers, employees and agents, harmless from and against any claims relating to the self-administration of such medication.
(f) A school district shall require that any back-up medication provided by the student’s parent or guardian be kept at the student’s school in a location to which the student has immediate access in the event of an asthma or anaphylaxis emergency.
(g) A school district shall require that information described in subsection (b)(3) and (4) be kept on file at the student’s school in a location easily accessible in the event of an asthma or anaphylaxis emergency.
(h) An authorization granted pursuant to subsection (b) shall allow a student to possess and use such student’s medication at any place where a student is subject to the jurisdiction or supervision of the school district or its officers, employees or agents.
(i) A board of education may adopt a policy pursuant to K.S.A. 72-1138(e), and amendments thereto, which that:
(1) Imposes requirements relating to the self-administration of medication which that are in addition to those required by this section; and
(2) establishes a procedure for, and the conditions under which, the authorization for the self-administration of medication may be revoked.
Sec. 7. K.S.A. 2025 Supp. 72-6283 is hereby amended to read as follows: 72-6283. (a) As used in this section, K.S.A. 65-1680 and 65-2872b, and amendments thereto:
(1) “Albuterol” means a short-acting beta-2 agonist-inhaled medication, otherwise known as a bronchodilator, that is prescribed by a physician or mid-level practitioner for the treatment of respiratory distress.
(2) “Albuterol metered-dose inhaler” means a portable drug delivery system containing a canister of multiple premeasured doses of albuterol in a device actuator.
(3) “Albuterol solution” means a liquid form of albuterol for use with a nebulizer.
(4) “Anaphylaxis” or “anaphylactic reaction” means a sudden, severe and potentially life-threatening multi-system allergic reaction.
(5) “Designated school personnel” means an employee, officer, agent or volunteer of a school who has completed training, documented by the school nurse, a physician or a mid-level practitioner, to administer emergency medication on a voluntary basis outside of the scope of employment.
(6) “Emergency medication” means epinephrine or albuterol.
(7) “Epinephrine” means a medication prescribed by a physician or mid-level practitioner for the emergency treatment of anaphylaxis prior to the arrival of emergency medical system responders.
(8) “Epinephrine auto-injector delivery system” means a device that automatically injects is approved by the federal food and drug administration, contains a premeasured dose of epinephrine and is used to administer epinephrine into the human body.
(9) “Mid-level practitioner” means the same as such term is defined in K.S.A. 65-1626, and amendments thereto.
(10) “Nebulizer” means a device that is used to change a liquid medication to a fine spray of liquid or mist for the administration of the medication through inhalation.
(11) “Pharmacist” means the same as such term is defined in K.S.A. 65-1626, and amendments thereto.
(12) “Physician” means any person licensed by the state board of healing arts to practice medicine and surgery.
(13) “Respiratory distress” means impaired ventilation of the respiratory system or impaired oxygenation of the blood.
(14) “School” means any school operated by a school district organized under the laws of this state or any accredited nonpublic school that provides education to elementary or secondary students.
(15) “School nurse” means a registered nurse licensed by the board of nursing to practice nursing in Kansas or a licensed practical nurse working under a registered nurse who is employed by a school to perform nursing services in a school setting.
(16) “Spacer” means a holding chamber that is used to optimize the delivery of aerolized albuterol from an albuterol metered-dose inhaler.
(17) “Stock supply” means an appropriate quantity of emergency medication as recommended by a physician or mid-level practitioner.
(b) (1) A school may maintain a stock supply of emergency medication upon obtaining a prescription from a physician or mid-level practitioner in the name of the school. A physician or mid-level practitioner shall review the school’s policies and procedures established pursuant to subsection (c) prior to prescribing such emergency medication.
(2) A stock supply of epinephrine may consist of one or more standard-dose or pediatric-dose epinephrine auto-injectors delivery systems. A school nurse or designated school personnel may administer such epinephrine in an emergency situation to any individual who displays the signs and symptoms of anaphylaxis at school, on school property or at a school-sponsored event if such school nurse or designated school personnel reasonably believes that an individual is exhibiting the signs and symptoms of an anaphylactic reaction.
(3) A stock supply of albuterol may consist of one or more albuterol metered-dose inhalers, one or more doses of albuterol solution and one or more spacers or nebulizers. A school nurse or designated school personnel may administer such albuterol in an emergency situation to any individual who displays the signs and symptoms of respiratory distress at school, on school property or at a school-sponsored event if such school nurse or designated school personnel reasonably believes that an individual is exhibiting the signs and symptoms of respiratory distress.
(c) A school that maintains a stock supply of emergency medication shall establish school policies and procedures relating to:
(1) Storage of the emergency medication, which shall require that the emergency medication is stored:
(A) In a safe location that is readily accessible to the school nurse or designated school personnel; and
(B) in accordance with manufacturer temperature recommendations;
(2) periodic monitoring of the inventory and expiration dates of emergency medication;
(3) administration of emergency medication by designated school personnel; and
(4) training requirements for designated school personnel, which shall be conducted by a school nurse, physician or mid-level practitioner on not less than on an annual basis for such designated school personnel. Such training shall include, but not be limited to, the following:
(A) Recognition of the symptoms of anaphylaxis and respiratory distress;
(B) administration of emergency medication;
(C) calling for emergency medical system responders;
(D) monitoring the condition of an individual after emergency medication has been administered;
(E) notification of the parent, guardian or next of kin; and
(F) safe disposal and sanitation of used equipment.
(d) A school shall publish information related to the school’s emergency medication policies and procedures and shall maintain records of the training provided to designated school personnel.
(e) A school may accept monetary gifts, grants and donations to carry out the provisions of this section or may accept epinephrine auto-injectors delivery systems, albuterol metered-dose inhalers, albuterol solution, spacers or nebulizers from a manufacturer or wholesaler.
Sec. 8. K.S.A. 72-6282 and K.S.A. 2025 Supp. 22-2312, 65-1680, 65-16,127 and 72-6283 are hereby repealed.
Sec. 9. This act shall take effect and be in force from and after its publication in the statute book.
Approved April 9, 2026.
